Discover Great Companies Discover Great Clients
Popularity  16.1万   |   Followers  67   |   Likes  35   |   Feedback  44 Claim this company

Research and development and industrialization of monoclonal antibody

No.228 Shanghai Popularity Ranking No.26 Xuhui District No.1 Kang Ti Yao No.2 Yi Yao Chuang Xin No.3 Dan Ke Long Kang Ti Yao Products No.3 Yi Zhi Agents No.3 Zhu She Liquids No.3 Dan Ke Long Kang Ti No.3 Dan Ke Long Kang Ti Yan Jiu No.4 Yi Yao Ji Group No.5 Antibodies No.8 Yuan Yan Yao No.8 Innovative Drugs Products No.10 Sheng Wu Ke Ji / Biotechnology Engineering 独角兽企业 高新技术企业 瞪羚企业 省级创新型中小企业 省级专精特新中小企业 市级创新型中小企业 GMP认证
More

Company Overview

  • Nature: Joint Venture Size: 1000-4999 employees Founded: 16年
  • Industry: Pharmaceuticals/Bioengineering
  • Full name: Shanghai Henlius Biotech, Inc.。

Development Stage

  • Stage: IPO, 。
  • Ranking: Ranked #228 in Shanghai by popularity Ranked #1 in Shanghai Kang Ti Yao Company by popularity Ranked #2 in Shanghai Yi Yao Chuang Xin Company by popularity Ranked #3 in Shanghai Dan Ke Long Kang Ti Yao Products Company by popularity Ranked #3 in Shanghai Yi Zhi Agents Company by popularity
  • Honors: 2025中国新经济500强 2023中国企业慈善公益500强 独角兽企业 高新技术企业 According to algorithm
  • News: 2026-03-20:复宏汉霖:2025年实现营收66.666亿元,同比增长16.5%。
  • Salary: 48.9% of positions earn 20-50K, In 2026 vs last yeargrew by 5%.。Master's salary: ¥25.2K, Doctorate salary: ¥33.8K.
  • R&D: "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 27.1%, "Medical & Health/Beauty & Healthcare": 24.8%, "Other (R&D and Technical)": 13.5%。
  • Recruiting: In 2026 vs 2025grew by 72%. Demand for highly educated talent: Master's: 126, Doctorate: 67.
  • Requirement: Education: 本科 leads with 37.2%. Experience: 不限 leads with 34.2%.
  • Region: Distributed across 14 regions, 上海: 70.4%, 北京: 7.8%, 广州: 2.2%, 南京: 1.7%.

About the Company

[Summary] Research and development and industrialization of monoclonal antibody

Henlius (2696.HK) is an international innovative biopharmaceutical company dedicated to providing affordable, high-quality biological medicines to patients worldwide. Its products cover oncology, autoimmune diseases, ophthalmology, and other therapeutic areas. Five products have been launched in China, one product internationally, with 18 indications approved, and three marketing applications accepted by China's NMPA, the U.S. FDA, and the EMA in Europe. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform with efficient and innovative core proprietary capabilities spanning the entire industry chain from R&D and manufacturing to commercial operations. The company has established a comprehensive and efficient global innovation center and conducts production and quality control in compliance with international Good Manufacturing Practice (GMP) standards, continuously strengthening its integrated manufacturing platform. Among these, the Xuhui base in Shanghai has obtained GMP certification from both China and the EU, while the Songjiang Base (Phase I) has also obtained China's GMP certification. Henlius has strategically laid out a diversified, high-quality product pipeline comprising more than 20 innovative monoclonal antibodies and is advancing combination immunotherapies based on its proprietary anti-PD-1 monoclonal antibody H药 汉斯状®. Following the successive approvals of the domestic* biosimilar Hanlikan® (rituximab), the China-developed and China-EU dual-approved monoclonal antibody Hanquyou® (trastuzumab; European trade name: Zercepac®, Australian trade names: Tuzucip® and Trastucip®), Handayuan® (adalimumab), and Hanbeita® (bevacizumab), the innovative product Hansizhuang® (serplulimab) has been approved to treat microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer, and extensive-stage small cell lung cancer, becoming the world's first anti-PD-1 monoclonal antibody approved as first-line treatment for small cell lung cancer. Its marketing application for esophageal squamous cell carcinoma is also under review. Furthermore, the company is concurrently conducting over 30 clinical trials across 16 products globally.

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Henlius Financing History (5 rounds)

Manage
IPO
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Market:
  • Deal:

Henlius How Fast Is Hiring Growing? (570 open positions)

Manage
?
Growth Rate
2026 vs 2025
  • 2025: Up 231%
  • 2024: Up 8%
  • 2023: Down 35%
  • 2022: Down 61%
Henlius Year-by-Year Hiring:
* Hiring was generally low during 2020-2022 due to the pandemic
Henlius Campus Recruitment & Advanced Degree Talent Demand
Graduates 28 Interns 12 Part-time 2 Master's 126 Doctorate 67
Note: How fast is hiring at Shanghai Henlius Biotech, Inc. growing? Henlius2026: 1391 openings (up 72%), 2025: 810 openings (up 231%), 2024: 245 openings (up 8%), 2023: 227 openings (down 35%), 2022: 350 openings (down 61%), 2021: 902 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Henlius Master's Degree Job Demand Analysis

(More)
?
Growth Rate
2026 vs 2025
  • 2025: Up 143%
  • 2024: Down 22%
  • 2023: Down 50%
  • 2022: Up 45%
Henlius Master's Hiring by Year:
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Shanghai Henlius Biotech, Inc. growing? HenliusMaster's recruitment over the years: 2025: 97 openings (up 143%), 2024: 40 openings (down 22%), 2023: 51 openings (down 50%), 2022: 103 openings (up 45%), 2021: 71 openings. Henlius master talent ranking in Shanghai: #15, Henlius master salary mostly around 20-50K.

Henlius Doctoral Degree Job Demand Analysis

(More)
+220%
Growth Rate
2026 vs 2025
  • 2025: Up 400%
  • 2024: Down 55%
  • 2023: Down 31%
  • 2022: Up 71%
Henlius Doctoral Hiring by Year: 2026 — 99 more jobs than 2025
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is doctoral hiring at Shanghai Henlius Biotech, Inc. growing? HenliusDoctorate recruitment over the years: 2026: 144 openings (up 220%), 2025: 45 openings (up 400%), 2024: 9 openings (down 55%), 2023: 20 openings (down 31%), 2022: 29 openings (up 71%), 2021: 17 openings. Henlius doctorate talent ranking in Shanghai: #4, Henlius doctorate salary mostly around 20-50K.

Henlius R&D Strength (Technical Talent Demand)

(More)
How is the demand for technical talent at Shanghai Henlius Biotech, Inc.? Based on an analysis of Henlius's job postings over the past year, "Biology/Pharmaceutical/Chemical/Environmental Protection" demand: 27.1%, "Medical & Health/Beauty & Healthcare": 24.8%, "Other (R&D and Technical)": 13.5%, "Scientific Research": 11.2%, "Computer/Network/Technology": 8.4%, "Mechanical/Instrumentation": 1.7%. For reference only.

Henlius — What Are the Salaries Like? (1160 records)

Manage
salary range: 2K - 50K, 48.9% of roles pay ¥20-50K
Note: salary statistics are based on 1160 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Shanghai Henlius Biotech, Inc.?Henlius48.9% of positions earn 20-50K, Fresh graduate salary: ¥11.0K。Shanghai salary ranking top 40,经营管理类 average salary ¥30.4K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Henlius

(More)
Are salaries high at Shanghai Henlius Biotech, Inc.? We provide: Pharmaceutical Sales Representative, Vice President, Senior Manager, Researcher, Intern, 临床, Analyst, QC, Regional Manager, 高级主管, Project Management, Medical Science Liaison, 科学家, 医学联络官, Marketing, QA, Sales, Management Manager, ma, Operations. Click to view detailed salary analysis by job.

Henlius — Fortune 500? (More)

Yes, ranked in 中国新经济500强:

  • NO.351 2025中国新经济500强 >
  • NO.443 2021中国新经济500强 >

Yes, ranked in 中国企业慈善公益500强:

  • NO.254 2023中国企业慈善公益500强 >

Job Category

  • 经营管理类
    27% of total 27%
  • 生物/制药/化工/环保类
    25.7% of total 25.7%
  • 销售类
    25.2% of total 25.2%
  • 医疗卫生/美容保健类
    24.4% of total 24.4%

Education

  • 本科
    37.2% of total 37.2%
  • 不限
    19.5% of total 19.5%
  • 硕士
    18.9% of total 18.9%
  • 大专
    13.7% of total 13.7%

Experience

  • 不限
    34.2% of total 34.2%
  • 5-10年
    25.1% of total 25.1%
  • 1-3年
    18.5% of total 18.5%
  • 3-5年
    17.6% of total 17.6%
View Detailed Analysis

What does Shanghai Henlius Biotech, Inc. require? Who is Henlius hiring? Henlius recruitment: 经营管理类占比最多占27%,其次是生物/制药/化工/环保类占25.7%. What education can get in at Henlius? 本科占比最多占37.2%,其次是不限占19.5%. High education required at Henlius? 硕士占18.9%,博士占10.3%. Work experience required at Henlius? 不限占比最多占34.2%,其次是5-10年占25.1%. Where are the job locations at Henlius? 上海占比最多占70.4%,其次是北京占7.8%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 54,349.4853万(元)
Legal Representative: 朱俊
Date Established:
Credit Code: 91310000550094566N
Registered Address: 中国(上海)自由贸易试验区盛荣路367号1号楼9层901室

Partners & Suppliers

欧璧中国为复宏汉霖提供预灌封注射器及包装组件。 Source
供应商 医药包装-玻璃容器
多宁生物向复宏汉霖提供实验室耗材及工艺解决方案 Source
供应商 生物制药客户
供应一次性生物工艺袋 Source
供应商 生物工艺一次性耗材
采购色谱填料和预装柱用于利妥昔单抗、曲妥珠单抗等生物类似药生产 Source
供应商 抗体药物
百因诺为其提供细胞培养基 Source
供应商 抗体药物

People who follow Henlius also follow

Henlius Competitors (Similar Companies)

制药/药业 诊断试剂 生物制药 干细胞
“Promoting human health”
“Research, development, and production of anti-tumor and surgical medic”
“Continuously innovating to bring patients medicines that significantly”
“In the rapidly growing biopharmaceutical field, accelerate and transfo”
“To develop high-quality biologics that are accessible and affordable f”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
“A renowned enterprise in China's liver disease and anti-tumor fields”
“Helping partners successfully develop new drugs, reducing R&D costs an”
“Gene technology benefits humanity”
“Technological innovation and commercial application of pharmaceutical ”
人用疫苗 动物保健品 动物保健 罕见病
“Global integrated biopharmaceutical enterprise”
“An innovative biopharmaceutical enterprise focusing on antibody drugs”
医药 生物医药 单克隆抗体药物 高通量筛选

Discover Great Companies, Discover Great Clients

上海公司名录 上海“Xuhui District”公司名录 上海“医药”公司名录 上海“制药/药业”公司名录 上海“生物医药”公司名录 上海“抗体药”公司名录 上海“药物研发”公司名录 附近的公司

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates